logo
Share SHARE
FONT-SIZE Plus   Neg

AVI BioPharma's Eteplirsen Meets PrimaryEndpoint For Duchenne Muscular Dystrophy

AVI BioPharma Inc. (AVII), a developer of RNA-based therapeutics, reported that treatment with eteplirsen met the primary efficacy endpoint in a randomized, double-blind, placebo-controlled Phase IIb study in boys with Duchenne muscular dystrophy or DMD. Eteplirsen administered once weekly at 30mg/kg over 24 weeks resulted in a statistically significant increase in novel dystrophin compared to no increase in the placebo group.

In the study, a shorter duration of eteplirsen treatment, 12 weeks, did not show a significant increase in novel dystrophin, despite administration of the drug at a higher dose, the company added. This finding suggests that a longer duration of dosing is required before meaningful levels of dystrophin are produced.

Eteplirsen is AVI's lead drug candidate that is systemically delivered for the treatment of a substantial subgroup of patients with DMD.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Online travel agency Priceline Group, Inc. on Wednesday reported an increase in profit for the first quarter from last year on double-digit revenue growth amid higher travel and room night bookings. Both adjusted earnings per share and quarterly revenues topped analysts' expectations. However, the company provided financial outlook for the second quarter below analysts' estimates. Time Warner Inc. (TWX) reported a profit for its first quarter ended March 31, 2016 that increased about 25 percent from the prior year. Revenues increased 3% and adjusted operating income grew 11% due to strong growth across all its operating divisions. It reaffirmed its 2016 adjusted earnings per share outlook. German telecom giant Deutsche Telekom AG reported Wednesday that its first-quarter net profit quadrupled on hefty stake sale gain. Revenues also increased on US strength, while domestic revenues were weak.
comments powered by Disqus
Follow RTT